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Abstract
Background: Patients with resected oral cavity squamous cell carcinoma (OCSCC) are often treated with adjuvant
radiation (RT) ± concomitant chemotherapy based on pathological findings. Standard RT volumes include all surgically
dissected areas, including the tumour bed and dissected neck. RT has significant acute and long-term toxicities
including odynophagia, dysphagia, dermatitis and fibrosis.
The goal of this study is to assess the rate of regional failure with omission of radiation to the surgically dissected
pathologically node negative (pN0) hemi-neck(s) compared to historical control, and to compare oncologic outcomes,
toxicity, and quality of life (QoL) profiles between standard RT volumes and omission of RT to the pN0 neck.
Methods: This is a multicentre phase II study randomizing 90 patients with T1–4 N0–2 OCSCC with at least one pN0
hemi-neck in a 1:2 ratio between standard RT volumes and omission of RT to the pN0 hemi-neck(s). Patients will be
stratified based on overall nodal status (nodal involvement vs. no nodal involvement) and use of concurrent
chemotherapy. The primary endpoint is regional failure in the pN0 hemi-neck(s); we hypothesize that a 2-year regional
recurrence of 20% or less will be achieved. Secondary endpoints include overall and progression-free survival, local
recurrence, rate of salvage therapy, toxicity and QoL.
Discussion: This study will provide an assessment of omission of RT to the dissected pN0 hemi-neck(s) on oncologic
outcomes, QoL and toxicity. Results will inform the design of future definitive phase III trials.
Trial registration: Clinicaltrials.gov identifier: NCT03997643. Date of registration: June 25, 2019, Current version: 2.0 on
July 11 2020.
Keywords: Head and neck cancer, Oral cavity, Radiotherapy, Recurrence, Survival, Quality of life, Randomized controlled
trial, De-escalation
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Background
Patients with resected squamous cell carcinoma of the oral
cavity (OCSCC) are at risk of locoregional failure recur-
rence (LRR), at either the tumour surgical bed or in the
neck. Postoperative radiotherapy (PORT) is often added
after surgical resection to reduce the risk of local and re-
gional recurrence in patients with high-risk features.
Guidelines generally recommend PORT in patients with
more than one lymph node involved, pT3 or pT4 primary
disease, lymphovascular invasion (LVI), perineural inva-
sion (PNI), close or positive margins, extranodal extension
(ENE), and sometimes for patients with lymph node in-
volvement of neck levels IV or V [1–4].
ENE and positive surgical margins are considered the
highest-risk pathological features, whereas the other ad-
verse features are considered ‘intermediate risk’. Patients
with high-risk features are generally offered concurrent
chemotherapy with PORT, based on a post-hoc analysis
two of randomized trials [5–7]. In patients with other
adverse features, there is limited randomized evidence of
the benefits of PORT alone [8–10]. Retrospective series
and comparisons with historical controls have shown re-
ductions in LRR and improvement in overall survival
(OS) with PORT [11–18].
RT treatment volumes after surgery generally include
the entire surgical bed, including the dissected hemi-
neck(s), and may include the contralateral undissected
neck at the discretion of the treating physician [19].
However, PORT is associated with significant acute and
late toxicities, including dysphagia, mucositis, xerosto-
mia, dermatitis, fibrosis, osteoradionecrosis, voice
changes, ototoxicity and hypothyroidism [7, 20]. Larger
RT treatment volumes are associated with increasing
toxicity. These large treatment volumes are based on
historical practice, without guidance from randomized
evidence. The benefit of treating the nodal regions in the
pathologically node negative (pN0) neck is unknown.
Retrospective studies looking at series of oral cavity
cancer patients in whom PORT was omitted altogether
have also demonstrated low rates of isolated nodal re-
currence ranging from 8 to 15% [21–23]. In their series
of 166 patients with mostly T1-T2 oral tongue tumours
with a pN0 neck treated with surgery alone (75%), PORT
to the primary site (8%) or PORT to the primary site
and neck (17%), So et al. reported a rate of isolated
nodal recurrence of 7–8% in all groups [21]. Mizrachi
et al. described a series of 558 patients with T1-T4 dis-
ease and pN0 neck with 65% not receiving PORT, with a
neck recurrence rate of 10% [22]. In Ganly et al., 164 pa-
tients with pT1-T2 pN0 oral tongue cancer without
PORT had an isolated regional recurrence rate of 15%,
with an additional 5% having a simultaneous locoregio-
nal recurrence. In this study depth of invasion was pre-
dictive of neck recurrence [23]. In a series of 127
patients with a pN1 neck, the neck recurrence-free sur-
vival was 85% in those receiving PORT vs 84% in those
without PORT [24]. It is difficult to draw comparisons
between groups receiving or not receiving PORT in
these retrospective studies since those receiving PORT
had more risk features.
Retrospective data from a small number of PORT vol-
ume studies also demonstrate good oncologic outcomes
in patients where radiation was omitted to the contralat-
eral clinically or pathologically N0 neck [25, 26]. In Veg-
eer et al. 123 patients with well-lateralized oral cavity or
oropharynx squamous cell carcinoma (SCC) were
treated with unilateral PORT, with 60% of patients N0
and 41% N1 or N2. Contralateral metastases developed
in only 6% of patients, with most successfully receiving
salvage therapy [25].
A recent non-randomized prospective phase II trial
eliminated PORT to the pN0 neck in 72 patients with
head and neck squamous cell carcinoma (HNSCC),
demonstrating excellent results with no isolated failures
and 97% control in the unirradiated pN0 neck. Twenty
percent of patients included in the study had oral cavity
tumours [27].
Taken together, the existing retrospective and pro-
spective data suggests that omitting PORT in patients
with a pN0 neck likely has a recurrence rate less than
15–20%. However, no randomized studies have directly
examined the omission of PORT in the pN0 neck. There
is also a paucity of data examining the effects of omis-
sion of PORT on QoL. We hypothesize that omitting
PORT to the hemi-neck(s) that have been dissected and
shown to be pN0 will be associated with acceptable rates
of regional recurrence and will improve quality of life
(QoL). The goal of this randomized phase II study is to
assess oncologic outcomes, functional outcomes, and
QoL in patients treated with PORT to the historically
standard volumes (usually including the primary site and
all dissected neck areas) vs. PORT only to the primary
site and pathologically involved hemi-neck, omitting ra-
diation to the pN0 hemi-neck(s).
Methods / design
Objectives
The objectives of this trial are to:
1. Compare regional recurrence rate to historical
controls with omission of PORT to the pN0 neck.
2. Compare oncologic outcomes, toxicity and QoL for
PORT (± chemotherapy) based on standard
treatment volumes (including the primary site
tumour bed, dissected neck ± elective nodal
regions) vs. PORT [± chemotherapy] that avoids
treating the dissected, pN0 neck.
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It is generally accepted that a risk of nodal recurrence
of 15–20% is sufficient to warrant radiation to a nodal
basin. Our hypothesis is that for patients with SCC of
the oral cavity, T1–4 N0–3 (as per AJCC 8th edition)
with at least one surgically dissected pN0 hemi-neck, the
regional failure rate will be 20% or less at 2 years when
treated with PORT omitting the pN0 neck.
Study design
This is an open-label phase II multi-centre randomized
trial. Patients will be randomized between current stand-
ard of care treatment (Arm 1) vs. omission of radiation
to the pN0 dissected hemi-neck(s) (Arm 2) in a 1:2 ratio
(Fig. 1). The required sample size is 90 patients. Stratifi-
cation factors include neck nodal status (pN0 vs pN+)
and use of chemotherapy. Patients will be recruited from
tertiary care centres (full list of participating sites avail-
able on clinicaltrials.gov, NCT03997643).
Primary endpoint
 Regional failure in the pN0 hemi-neck(s)
Secondary endpoints
 OS




 Rate of salvage treatment (surgery ± radiotherapy) in
the pN0 neck, and freedom from unsalvageable neck
recurrence
 QoL at 1 year, assessed with the MD Anderson
Dysphagia Inventory (MDADI) [28], the European
Organisation for Research and Treatment of Cancer
(EORTC) Quality of Life Cancer Patients general
(QLQ-C30) [29] and head & neck (H&N35) scales
[30], the EuroQOL 5-Dimension 5-Level (EQ-5D-
5L) [31], and the Neck Dissection Impairment Index
(NDII) [32]
 QoL measured at treatment completion and 6, 12,
15,18, 24, 30, 36, 42, 48, 54 and 60 months,
measured with MDADI, EORTC QLQ-C30,
H&N35, EQ-5D-5L and NDII
 Rate of feeding tube insertion after start of radiation
(either gastric, gastrojejeunal, or nasogastric) and
rate of feeding tube use at 1-year post-
randomization.
 Swallowing function at 1-year, assessed by Modified
Barium Swallow (MBS) study and measured by the
Modified Barium Swallow Impairment Profile
(MBSImP™©) score [33], the Dynamic Imaging
Grade of Swallowing Toxicity (DIGEST™) score [34],
and the Functional Oral Intake Scale (FOIS) [35].
 Toxicity, assessed using the National Cancer
Institute Common Toxicity Criteria (NCI-CTC)
version 4.03
 Rate of failure in the clinically node negative neck, if
applicable (i.e. the undissected node-negative neck,
for well-lateralized tumours).
Inclusion criteria
 Age 18 years or older
 Willing to provide informed consent
 Eastern Cooperative Oncology Group (ECOG)
performance status 0–2
 Resected OCSCC with at least an ipsilateral selective
neck dissection. The oral cavity includes: lips, buccal
Fig. 1 Study schema
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mucosa, oral tongue, floor of mouth, gingiva,
retromolar trigone, and hard palate
 Patient has at least one pathological feature that is
an indication for PORT: positive or close (≤ 3 mm)
margin, presence of LVI or PNI, pT3 or pT4 disease,
positive lymph nodes, or ENE
 PORT is recommended by the treating physician
 Pathologically lymph node negative in at least one
dissected hemi-neck with at least 10 nodes recov-
ered in each pN0 hemi-neck, after a dissection that
at minimum includes nodal levels 1–3 in the pN0
hemi-neck(s).
 Radiation contours have been peer-reviewed and
approved
Exclusion criteria
 Patients with an ipsilateral neck dissection only with
positive lymph nodes, unless they undergo a
contralateral neck dissection that is pN0
 Patients with bilaterally involved neck nodes
 Patients with pT3-T4 tumours involving midline
who undergo an ipsilateral neck dissection (unless a
contralateral neck dissection is performed)
 Serious medical comorbidities or other
contraindications to radiotherapy
 Prior history of head and neck cancer within 5 years
 Any other active invasive malignancy, except non-
melanotic skin cancers, low-risk prostate cancer, and
Stage I-IVA papillary or follicular thyroid cancer.
 Prior head and neck radiation at any time
 Prior oncologic head and neck surgery in the oral
cavity or neck.
 Known metastatic disease
 Locoregional disease recurrence identified following
surgical resection but prior to start of radiotherapy
 Inability to attend full course of radiotherapy or
follow-up visits
 Unable or unwilling to complete QoL questionnaires
 Pregnant or lactating women
Pre-treatment evaluation
 History and physical examination by a radiation
oncologist within 5 weeks prior to randomization
 Staging prior to randomization:
CT or MRI of the neck (with contrast unless
contraindicated) within 14 weeks of
randomization. This can include the pre-operative
CT, or the radiation therapy CT or MRI simula-
tion if reviewed by a radiologist.
▪ In some instances, suspicious lymph nodes are
visible on the scan after surgery. In such
instances, recurrence must be ruled out
pathologically before enrollment, either with a
needle biopsy or resection of these nodes.
CT of the chest or whole body PET-CT (usu-
ally prior to surgery, must be within 14 weeks of
randomization)
 Histological confirmation of SCC
 Pregnancy test for women of child-bearing age
within 2 weeks of randomization
 Dental evaluation prior to starting treatment, except
edentulous patients
 Assessment of dysphagia using NCI-CTC version
4.03 within 2 weeks of treatment initiation
 Completion of QoL scoring prior to initiation of
treatment
 Prior to randomization, radiation contours are to be
peer-reviewed and approved
 MBS at baseline prior to initiation of treatment with
documentation of the MBSIimP™©, DIGEST™ and
the FOIS scores
Treatment plan
Surgical resection, and adjuvant radiotherapy and
chemotherapy will be delivered in accordance with Na-
tional Comprehensive Cancer Network (NCCN) Clinical
Guidelines [1].
Primary tumours should be resected en bloc whenever
possible with the goal of achieving clear margins. Pa-
tients with midline involvement of the primary tumour
should receive a bilateral neck dissection.
Adjuvant cisplatin-based chemotherapy concurrent
with radiotherapy is at the discretion of the treating
medical oncologist, and is recommended for patients
with positive margins or ENE (for patients who can tol-
erate chemotherapy). For patients who are deemed unfit
or too elderly (> 70 years of age) for cisplatin-based
chemotherapy, the standard dose and/or schedule can
be modified, alternative systemic therapy regimens
maybe used (eg. weekly carboplatin, Calais regimen), or
systemic therapy can be omitted at the discretion of the
treating physicians. It is strongly recommended that ra-
diation starts within 6 weeks of the date of surgery, and
it is mandatory to start no more than 7 weeks after the
date of surgery.
During treatment, supportive care should be in ac-
cordance with local standard of care, which often in-
cludes speech language pathology (SLP) assessment. Any
SLP interventions (e.g. providing swallowing exercises)
should be the same in both arms and conform to local
standard of care.
Dose/fractionation In both arms, a dose of 60 Gy in 30
fractions will be delivered to the operative bed target
volumes. Centres that normally treat dissected, node-
negative levels to 54 Gy in 30 fractions will be permitted
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to do so, if used consistently for all patients on trial.
Areas of positive margins or ENE should receive 64 Gy
in 30 fractions if those areas can be localized. Undis-
sected areas that require coverage, in the opinion of the
treating radiation oncologist (e.g. low neck, retrostyloid
space), should receive 54 Gy in 30 fractions (Table 1).
Immobilization and localization All patients will be
immobilized in a custom thermoplastic shell and will
undergo a planning CT simulation (with or without
IV contrast) encompassing the head and neck to
below the clavicles. The planning CT will be fused
with other diagnostic imaging (e.g. MRI scans or pre-
operative CT) where necessary. Bite blocks / tongue
depressors / jaw separators may be used as per insti-
tutional protocol; these must be determined at the
time of planning CT, prior to contour generation and
patient randomization.
Radiotherapy volume definitions A randomization vol-
ume will be defined as the nodal volume in the dissected
pN0 hemi-neck(s). The randomization volume will de-
pend on the laterality of the neck dissection performed
(ipsilateral vs. bilateral), and whether pathologically in-
volved nodes are present in the neck dissection, defined
in Fig. 2. Patients with bilaterally involved neck nodes
are ineligible. Patients with a unilateral neck dissection
with positive lymph nodes are ineligible unless they
undergo a staged neck dissection of the opposite side
that is pN0.
Standard treatment volumes (Arm 1): If randomized
to Arm 1, all contoured volumes, including the
randomization volume will be treated.
Omission of pN0 neck (Arm 2): If randomized to
Arm 2 the randomization volume will be omitted from
treatment planning.
Clinical Target Volumes (CTV):
The following radiation volumes will be contoured for
all patients prior to randomization (Table 1). The suffix
“pos” denotes CTVs in the node-positive hemi-neck, and
the suffix “neg” denotes the CTVs in the node-negative
hemi-neck.
1) High-risk volume (CTV64): regions corresponding
to positive margins or ENE, if present, and if those
areas can be localized.
2) Primary tumour operative bed (CTVp60):
surgically dissected areas corresponding to the
resected primary tumour, typically including the
pre-operative tumour area and any flap reconstruc-
tions and clips with a margin.
3) Involved neck:
a. Surgically dissected involved neck nodal
volume (CTVn60pos): surgically dissected neck
levels in the node-positive hemi-neck, if applic-
able. In the dissected neck, some centres rou-
tinely treat only involved nodal areas to 60 Gy
and the remainder of the dissected neck to 54
Gy. For centres where this is standard, this ap-
proach is acceptable, but all patients enrolled
from these centres must be treated with this ap-
proach. The areas treated to 54 Gy would be in-
cluded in a CTVn54pos.
b. Optional uninvolved low-risk neck on the in-
volved side (CTVn54pos): low-risk undissected
neck nodal volume on the involved side, if ap-
plicable at the discretion of the radiation on-
cologist. This may include the standard
lymphatic drainage sites not dissected at the
time of surgery in the node positive hemi-neck
such as the nodal levels below or above the dis-
sected areas (e.g. level IVb, retrostyloid space).
4) “Randomization Volume” corresponding to the
Uninvolved neck:
a. Surgically dissected involved neck nodal
volume (CTVn60neg): surgically dissected
neck levels in the node negative hemi-neck. In
centres that routinely treat the pN0 neck to 54
Gy, that dose is acceptable, but all patients must
be treated with that approach. In such centres,
these areas treated to 54 Gy would be included
in a CTVn54neg.
b. Optional uninvolved low-risk neck on the
uninvolved side (CTVn54neg): low-risk undis-
sected neck nodal volume on the uninvolved
side, if applicable at the discretion of the
Table 1 Radiation treatment volumes and doses
PTV Volume CTV Volumes Included Dose in
30
fractions
Arm 1 Arm 2
PTV64
Areas of positive margin or ENE





CTVp60 CTVn60pos 60 Gy
PTV54
(optional)
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radiation oncologist. In a patient who has had a
unilateral neck dissection that was pN0, this
may include the contralateral clinically node
negative (cN0) neck if that is standard institu-
tional practice
If randomized to omission of PORT to pN0 neck
(Arm 2), the CTVn60neg and CTV54neg contours are
deleted after randomization, prior to treatment planning.
To prevent bias, contours cannot be changed after
randomization. Local peer review of contours must take
place before randomization occurs. An overview of the
protocol timeline is shown in Fig. 3.
Planning Target Volumes (PTV):
A 3–5 mm expansion is used around the combined
CTVs (Table 1) to create the PTV, as per institutional
setup and protocol.
Radiotherapy planning Intensity modulated radiother-
apy (IMRT) photon therapy or proton therapy will be
used for all patients in this study. IMRT can be delivered
using static-beam techniques or rotational techniques
(e.g. Tomotherapy or Volumetric Modulated Arc Ther-
apy [VMAT]). If protons are used the dose will be re-
ported in Gy (relative biological effectiveness [RBE])
where the proton dose is multiplied by an RBE of 1.1.
All reported doses in Gy are considered equivalent. Cen-
tres with proton therapy will use their institutional
standard planning and delivery techniques.
All plans will be normalized to ensure that 95% of
each PTV is covered by 95% of the prescription dose
for that volume. An exception will be allowed for
centres that normally prescribe in such a manner that
95% of the PTV be covered by 100% of the prescrip-
tion dose, and such centres must pre-specify this be-
fore enrolling the first patient, and all subsequent
patients must be planned in the same manner. A
modified PTV cropped 3-5 mm from the external
contour for dose evaluation may be used as per insti-
tutional guidelines.
Fig. 2 The “Randomization Volume” corresponds to the pN0 hemi-neck(s). The neck volumes included in the “Randomization Volume” depend
on whether the patient had an ipsilateral vs. bilateral neck dissection, and the pathological findings in each hemi-neck(s). Patients with bilaterally
involved neck nodes are ineligible. Patients with an ipsilateral neck dissection with positive lymph nodes are ineligible unless they undergo a
contralateral neck dissection that is pN0. If randomized to standard treatment volumes (Arm 1), all contoured volumes, including the
“Randomization Volume” will be treated. If randomized to omission of the pN0 neck (Arm 2), the “Randomization Volume” will be omitted from
treatment planning
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The maximum dose to PTV64 (or PTV60 if no PTV64
present) should not exceed 110% of the prescribed dose,
and no volume > 1 cc outside of these PTVs should re-
ceive > 105% of the prescription dose.
Organs at Risk (OAR) definitions, dose constraints and
planning priorities are adapted from the following proto-
cols: RTOG protocols 1016 [36] (Arm 1) and RTOG 0920
[37] (Arm 2), NCIC-CTG HN6, ORATOR [38, 39] and
ORATOR2 [40], and are described in Additional file 1.
Quality assurance (QA) In order to ensure patient
safety and effective treatment delivery, a robust QA
protocol is incorporated. The following requirements
must be completed for each patient:
 Prior to randomization, each set of contours will be
peer-reviewed, either by another individual radiation
oncologist or at a team head and neck QA rounds.
 All dose delivery for intensity-modulated plans (in-
cluding arc-based treatments) will be confirmed be-
fore treatment by physics staff.
Cone-beam CT and/or orthogonal x-rays will be used
on a daily basis to verify treatment positioning, as per in-
stitutional standard practice.
Credentialling Prior to enrolling patients, each centre
will be given a sample CT dataset through secure file
transfer protocol (FTP) for contouring, planning and
physics QA. Enrollment can begin once the plan and
QA have been approved at the London Regional Cancer
Program. Centres who have been accredited for ORA-
TOR [38] or ORATOR2 [40] are exempt from this
requirement.
Participant discontinuation / withdrawal
Participants may voluntarily discontinue participation in
the study at any time. If a participant is removed from
the study, the clinical and laboratory evaluations that
would have been performed at the end of the study
should be obtained. If a participant is removed because
of an adverse event, they should remain under medical
observation as long as deemed appropriate by the treat-
ing physician.
Follow-up evaluation
Day 1 of follow-up will be the first day of radiotherapy.
Follow-up will consist of history and physical examin-
ation with laryngopharyngoscopy, CT imaging of the
neck ± thorax, QoL assessments and MBS. The follow-
up schedule is shown in Additional file 2. Additional im-
aging or laboratory investigations should be carried out
at the discretion of the oncologist, based on findings in
the history or physical examination. Additional treat-
ment (e.g. salvage treatment with surgery or further
radiotherapy) is at the discretion of the treating physi-
cians but will be recorded in the case report form.
Measurement of outcomes
 pN0 neck failure: measured as time from
randomization until disease recurrence in the
initially pN0 hemi-neck(s). Patients with prior or
simultaneous recurrence at the primary site or in
the initially pN+ hemi-neck will be censored for this
outcome as of that timepoint. The primary endpoint
is a comparison of pN0 neck failure in Arm 2 vs.
historical controls; this endpoint will also be com-
pared between the two arms as a secondary
endpoint.
 OS: measured as time from randomization until
death from any cause.
Fig. 3 Flowchart showing timing of randomization with respect to
peer review and treatment planning. Contours must be finalized
before randomization and may not be changed after randomization
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 DFS: measured as time from randomization to
either recurrence at any location or death,
whichever occurs first. New primary tumours will
not count as DFS events.
 Local recurrence: measured as time from
randomization until disease recurrence at the
primary site.
 Regional recurrence: measured as time from
randomization until disease recurrence anywhere in
the neck.
 Locoregional recurrence: measured as time from
randomization until disease recurrence anywhere in
the neck or at the primary site, whichever occurs
first.
 Recurrence in the pN0 neck without other
locoregional recurrence: measured as time from
randomization until disease recurrence in the pN0
neck alone without recurrence at the primary site or
pN+ neck.
 Rate of salvage surgery and/or radiation in pN0
neck: measured as time from randomization to
salvage intervention (surgery ± radiation) in the pN0
neck. Freedom from unsalvageable neck recurrence
will be reported as the time from randomization to
development of a neck recurrence in the pN0 neck
that could not be salvaged.
 Feeding Tube Insertion: Rate of feeding tube
insertion after start of radiation (either gastric,
gastrojejeunal, or nasogastric) and rate of feeding
tube use at 1-year post-randomization. Patients with
feeding tubes inserted prior to randomization will be
censored for this endpoint.
 Rate of failure in the clinically node negative
neck: for patients who have unilateral neck
dissections, the cN0 neck may be treated with
radiation or observed, at the discretion of the
treating oncologist (see section 6). This is measured
as the time from randomization to failure in the cN0
neck, and will be reported for the whole group of
patients who had unilateral dissections, and also
stratified by whether radiation was delivered to that
area.
Enrollment, randomization and allocation
Patients will be enrolled by dedicated clinical trials staff
and/or the investigator at each participating institution.
Patients will randomized in a 1:2 ratio to standard radi-
ation volumes (Arm 1) vs omission to the pN0 neck
(Arm 2). A permuted block design with two stratifica-
tion factors will used with the size of the blocks known
only to the statistician, stratified based upon overall neck
nodal status (pN0 vs. pN+) and use of concurrent
chemotherapy (yes vs. no). Randomization sequences are
generated for each strata separately with a random
number generator based on permuted block design. This
gets formatted as a CVS file which gets uploaded into
REDCap [41].
Statistical considerations
Sample size The primary endpoint is the rate of relapse
in the pN0 neck (i.e. the regional relapse rate in the pN0
neck) in Arm 2, compared to historical controls. All
other endpoints are a comparison between Arm 1 and
Arm 2.
It is generally accepted that a risk of nodal recurrence
of 15–20% is sufficient to warrant radiation to a nodal
basin, and therefore we wish to exclude a risk of regional
recurrence in the pN0 neck of 20% at 2-years. Using a
one-sided, one-sample binomial test, allowing for 5%
dropout, a sample size in Arm 2 of 60 patients provides
83.1% power at a 0.05 significance level to detect a re-
gional control rate in the pN0 neck of 92%, compared to
an unacceptable level of 80%.
This sample size (30 in Arm 1 and 60 in Arm 2) also
allows for > 80% power to detect a 10-point difference in
the total MDADI score at 1 year (a secondary endpoint),
assuming the scores are normally distributed with a
standard deviation of 15 in each arm. It is generally be-
lieved that a 10-point difference in standardized QoL
scores represents a clinically significant difference in
QoL [42]. It is assumed that the QoL scores will be nor-
mally distributed with a standard deviation of 15 in each
arm. The MDADI will be calculated as the composite
score, but will also be reported for each of the subscales.
Analysis plan
Patients will be analyzed in the groups to which they are
assigned (intention-to-treat). Oncologic outcomes and
OS will be calculated from date of randomization using
the Kaplan-Meier method. A one-sided, one-sample bi-
nomial test will be used for the primary endpoint as de-
scribed above. For actuarial comparisons between arms,
the stratified log-rank test will be used (stratified by
stratification factors). An two-sample T-test will be used
to compare QoL scores at 1-year. The percentage of pa-
tients in each arm who experience a clinically significant
QoL decline on the MDADI (10 points) will also be
reported.
MBSImP™© scores will be compared at 1-year, includ-
ing the total score, and the scores on the oral and
pharyngeal subscales, using a two-sample T-test or a
Wilcoxon rank sum test as appropriate. DIGEST™ and
FOIS scores will be compared using the Chi-square test.
Pre-planned subgroup analysis will occur based on the
stratification variables (nodal status [pN0 vs. pN+] and
use of concurrent chemotherapy), as well as based on
the neck dissection performed (unilateral vs. bilateral),
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and T-stage (T1–2 vs. T3–4). There will also be a pre-
planned analysis based on the extent of nodes harvested
in the pN0 neck (< 18 vs. 18 or more), depth of invasion
of the primary tumour (< 4 mm vs. 4 mm or more), and
photon versus proton treatment.
Multivariable Cox proportional hazards or logistic re-
gression analysis, as appropriate, will be used to deter-
mine baseline and pathologic factors predictive of pN0
neck failure, DFS, OS, locoregional recurrence and sal-
vage therapy. For the secondary endpoints involving
QoL scales, linear mixed effects models will be used; for
the MDADI, the total scores will be compared between
the two arms, whereas for the EORTC QLQ-C30 and
H&N35 scales, each of the subscales (e.g. pain, swallow-
ing, etc.) will be compared between the two arms.
Rates of grade ≥ 2 toxicity and use of feeding tubes will
be compared between arms using the Chi-square or
Fisher’s exact test, as appropriate.
Utilities will be calculated from the EQ-5D-5L which
will be administered at baseline and at 6 month intervals.
Quality adjusted life years (QALYs) will be assessed as
the area under the preference-weighted survival curve.
Overall costs of each treatment strategy will be ab-
stracted from the available literature. The incremental
cost effectiveness ratios (ICERs) between treatment arms
will be compared through the standard method of ratio
between differences in costs and QALYs. Point estimates
for these differences can be derived from multivariable
generalized estimating equations (GEE) or generalized
linear model (GLM) analyses.
Data safety monitoring committee
The Data Safety Monitoring Committee (DSMC), con-
sisting of at least one radiation oncologist and one med-
ical oncologist not involved in the study, will meet every
6 months after study initiation. Toxicity outcomes will
be monitored, but since the experimental arm involves
smaller radiation volumes, it is extremely unlikely that
toxicity would be higher in the experimental arm, and
therefore no stopping rules for toxicity are included.
Interim analysis The DSMC will conduct one interim
analysis once 45 patients have been accrued and com-
pleted the 6-month QoL questionnaires. For this ana-
lysis, the DSMC will be blinded to the identity of each
treatment arm, but QoL, recurrence in the pN0 neck,
OS, and DFS estimates at 2-years will be presented for
each arm.
The DSMC will recommend stopping the trial if there
is an OS difference that is statistically significant with a
threshold of p < 0.001 using the stratified log-rank test,
based on the Haybittle-Peto stopping rule; this retains
an overall alpha of 0.05.
Ethical considerations
The Principal Investigator will obtain ethical approval
and clinical trial authorization by competent authorities
according to local laws and regulations. The World
Health Organization (WHO) Trial Registration Data Set
is shown in Additional file 4.
Institutional review board (IRB) / research ethics
board (REB) The protocol (and any amendments), the
informed consent form, and any other written informa-
tion to be given to subjects will be reviewed and ap-
proved by a properly constituted IRB/REB operating in
accordance with the current federal regulations (e.g.,
Canadian Food and Drug Regulations (C.05.001); US
Code of Federal Regulations (21CFR part 56)), ICH GCP
and local regulatory requirements. A letter to the inves-
tigator documenting the date of the approval of the
protocol and informed consent form will be obtained
from the IRB/REB prior to initiating the study. Any in-
stitution opening this study will obtain IRB/REB ap-
proval prior to local initiation.
Informed consent The written informed consent form
(Additional file 3) to be provided to potential study sub-
jects should be approved by the IRB/REB and adhere to
ICH GCP and the ethical principles that have their ori-
gin in the Declaration of Helsinki. The investigator is re-
sponsible for obtaining written informed consent from
each subject, or if the subject is unable to provide in-
formed consent, the subject’s legally acceptable repre-
sentative, prior to beginning any study procedures and
treatment(s). The investigator should inform the subject,
or the subject’s legally acceptable representative, of all
aspects of the study, including the potential risks and
benefits involved. The subject should be given ample
time and opportunity to ask questions prior to deciding
about participating in the study and be informed that
participation in the study is voluntary and that they are
completely free to refuse to enter the study or to with-
draw from it at any time, for any reason.
Informed consent documentation must be signed and
dated by the subject, or the subject’s legally acceptable
representative, and by the individual who conducted the
informed consent discussion. A copy of the signed and
dated written informed consent form should be given to
the subject or the subject’s legally acceptable representa-
tive. The process of obtaining informed consent should
be documented in the patient source documents.
Confidentiality of subject records The names and per-
sonal information of study participants will be held in
strict confidence. All study records (case report forms
[CRFs], safety reports, correspondence, etc.) will only
identify the subject by initials and the assigned study
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identification number. The data coordinator will main-
tain a confidential subject identification list (Master List)
during the course of the study. Access to confidential in-
formation (i.e., source documents and patient records) is
only permitted for direct subject management and for
those involved in monitoring the conduct of the study
(i.e., sponsors, representatives of the IRB/REB, and regu-
latory agencies). The subject’s name will not be used in
any public report of the study.
Data storage All data will be stored on REDCap [41] a
secure web application for building and managing online
databases commonly used in the clinical trials research
community. Ongoing auditing will be performed by the
London Regional Cancer Program (LRCP) clinical trials
unit, independent from the trial investigators and
sponsor.
Adverse events The severity of adverse events will be
evaluated using the NCI-AE) version 4.03 grading scale
[43]. Any grade 4 or 5 adverse event that is definitely,
probably, or possibly the result of protocol treatment
must be reported to the Principal Investigator and Cen-
tral Office within 24 h of discovery. The Serious Adverse
Event (SAE) report form is to be completed with all
available information and uploaded to the REDCap SAE
page. The Central Office must be notified by email or
telephone that a new SAE form has been uploaded into
REDCap. It is the responsibility of each local Principal
Investigator to report all SAEs to their REB as per local
REB requirements. The Principal Investigator should
also comply with the applicable regulatory require-
ment(s) related to the reporting of unexpected serious
adverse drug reactions to the regulatory authority(ies).
Protocol amendments and trial publication Any mod-
ifications to the trial protocol must be approved and
enacted by the Principal Investigator (current version:
2.0 on July 11, 2020). Protocol amendments will be com-
municated to all participating centres, investigators,
IRBs, and trial registries by the Principal Investigator.
Any communication or publication of trial results will
be led by the Principal Investigator, and is expected to
occur within 1 year of the primary analysis. Trial results
will remain embargoed until conference presentation of
an abstract or until information release is authorized.
Authorship of the trial abstract and ultimately the full
manuscript will be decided by the Principal Investigator
at the time of submission. Professional writers will not
be used for either abstract or manuscript preparation.
Discussion
Patients with OCSCC at increased risk of recurrence are
often treated with PORT (± chemotherapy). Current
radiation volume recommendations include treatment of
the entire surgically dissected area, including the primary
tumour bed and the dissected neck(s). Limited prospect-
ive and retrospective evidence suggests that the risk of
recurrence in the clinically or pathologically negative
neck not treated with PORT is low [22, 25, 44].
PRESERVE is a phase II multi-centre trial that aims to
randomize 90 patients between standard treatment vol-
umes (Arm 1) and omission of radiation to the patho-
logically node negative dissected hemi-neck(s). The trial
will assess the safety of omitting the pN0 neck from the
treatment volume by comparing the regional recurrence
rate to historical controls, and will allow for compari-
sons of regional recurrence, OS, and QoL between the
two interventions. To date, no randomized studies exist
examining omission of radiation to the uninvolved neck.
Results of PRESERVE are expected to provide data that
will further inform future phase III randomized trials,
and has the potential to guide improvements in QoL for
patients with OCSCC worldwide.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13014-020-01636-x.
Additional file 1. Dose constraints, OAR definitions, planning priorities.
Additional file 2. Follow-up evaluation schedule.
Additional file 3. Study information and consent form.
Additional file 4. WHO trial registration data set.
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